The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Down-Regulation of LATS1 and LATS2 mRNA Expression by Promoter Hypermethylation and Its Association with Biologically Aggressive Phenotype in Human Breast Cancers
Abstract
Purpose: LATS1 and LATS2 are tumor suppressor genes implicated in the regulation of cell cycle. Methylation status of the promoter regions of these genes as well as its correlation with their mRNA levels were studied in human breast cancers. Correlation of LATS1 and LATS2 mRNA levels with clinicopathologic characteristics of breast tumors were also studied. Experimental Design: Methylation status of promoter regions of LATS1 and LATS2 was studied by a methylation-specific PCR and mRNA expression levels of LATS1 and LATS2 were determined by a real-time PCR assay in 30 breast cancers. In addition, correlation of LATS1 and LATS2 mRNA levels with clinicopathologic characteristics was studied in 117 breast cancers. Results: Methylation-specific PCR showed that of 30 tumors, LATS1 promoter region was hypermethylated in 17 tumors (56.7%) and LATS2 promoter region was hypermethylated in 15 (50.0%) tumors. LATS1 mRNA levels in breast tumors with hypermethylation (2.15 ± 0.37, mean ± SE) were significantly (P < 0.01) lower than those without hypermethylation (6.09 ± 1.38), and LATS2 mRNA levels in breast tumors with hypermethylation (1.42 ± 0.66) were also significantly (P < 0.01) lower than those without hypermethylation (3.10 ± 1.00). The decreased expression of LATS1 or LATS2 mRNA was significantly associated with a large tumor size, high lymph node metastasis, and estrogen receptor and progesterone receptor negativity. Furthermore, the decreased expression of LATS1 mRNA, but not LATS2 mRNA, was significantly (P < 0.05) associated with a poor prognosis. Conclusions: Hypermethylation of the promoter regions of LATS1 and LATS2 likely plays an important role in the down-regulation of their mRNA levels in breast cancers, and breast cancers with a decreased expression of LATS1 or LATS2 mRNA levels have a biologically aggressive phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
A gene hypermethylation profile of human cancer.
Esteller, M., Corn, P. G., Baylin, S. B., & Herman, J. G. (2001) · PubMed · Cited by 2,032
Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., & Sidransky, D. (1995) · Nature Medicine · doi:10.1038/nm0795-686 · Cited by 1,986
Herman, J. G., Merlo, A. U., Mao, L., Lapidus, R. G., Issa, J. J., Davidson, N. E., Sidransky, D., & Baylin, S. B. (1995) · PubMed · Cited by 1,341
Justice, R. W., Zilian, O., Woods, D. F., Noll, M., & Bryant, P. J. (1995) · Genes & Development · doi:10.1101/gad.9.5.534 · Cited by 977
Xu, T., Wang, W., Zhang, S., Stewart, R. A., & Yu, W. (1995) · Development · doi:10.1242/dev.121.4.1053 · Cited by 799
Inactivation of the Retinoblastoma Susceptibility Gene in Human Breast Cancers
Lee, E. Y.-H. P., To, H., Shew, J.-Y., Bookstein, R., Scully, P., & Lee, W.-H. (1988) · Science · doi:10.1126/science.3388033 · Cited by 581
Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction
St John, M. A. R., Tao, W., Fei, X., Fukumoto, R., Carcangiu, M. L., Brownstein, D. G., Parlow, A. F., McGrath, J., & Xu, T. (1999) · Nature Genetics · doi:10.1038/5965 · Cited by 439
DNA methylation and gene silencing in cancer: which is the guilty party?
Clark, S. J., & Melki, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205598 · Cited by 287
Cited by
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
The Hippo Signaling Pathway in Development and Cancer
Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.09.011 · Cited by 2,269
The Hippo pathway and human cancer
Harvey, K. F., Zhang, X., & Thomas, D. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3458 · Cited by 1,842
A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors
Voorhoeve, P. M., le Sage, C., Schrier, M., Gillis, A. J. M., Stoop, H., Nagel, R., Liu, Y.-P., van Duijse, J., Drost, J., Griekspoor, A., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.037 · Cited by 1,264
The Hippo–YAP pathway in organ size control and tumorigenesis: an updated version
Zhao, B., Li, L., Lei, Q., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1909210 · Cited by 1,144
Metadata
- Authors
- Takahashi, Y., Miyoshi, Y., Takahata, C., Irahara, N., Taguchi, T., Tamaki, Y., & Noguchi, S.
- Venue
- Clinical Cancer Research
- Published
- 2005-02-15
- Volume
- 11
- Issue
- 4
- Pages
- 1380-1385
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2156422948
- Cited by
- 279
- References
- 25
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Down-Regulation of LATS1 and LATS2 mRNA Expression by Promoter Hypermethylation and Its Association with Biologically Aggressive Phenotype in Human Breast Cancers. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-1773
- The paper
- Takahashi, Y., Miyoshi, Y., Takahata, C., Irahara, N., Taguchi, T., Tamaki, Y., & Noguchi, S. (2005). Down-Regulation of LATS1 and LATS2 mRNA Expression by Promoter Hypermethylation and Its Association with Biologically Aggressive Phenotype in Human Breast Cancers. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-1773
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.